Abstract: Embodiments of a method and/or system can include generating a co-amplified mixture based on co-amplifying a set of nucleic acid molecules (e.g., cell-free nucleic acids, etc.) from the biological sample, wherein the set of nucleic acid molecules includes a genomic region of interest associated with the medical condition; and a homologous native genomic region with partial sequence similarity to the genomic region of interest; sequencing the co-amplified mixture; determining an abundance metric for the genomic region of interest and an abundance metric for the homologous native genomic region; and/or facilitating the characterization of the medical condition based on the abundance metric for the genomic region of interest and the abundance metric for the homologous native genomic region.

Abstract: Aspects of the subject disclosure may include, for example, a device that facilitates transmitting electromagnetic waves along a surface of a physical transmission medium without requiring an electrical return path that facilitates delivery of electric energy to devices, and sensing a condition that is adverse to the electromagnetic waves propagating along the surface of the physical transmission medium. Other embodiments are disclosed.

Abstract: The present invention refers to a device, comprising a hollow body having at least one open end comprising at least one solid matrix binding, adsorbing, absorbing, chelating or retaining compounds which are not desired in a sample and preferably at least one barrier which is non-permeable for liquids and solids under ambience conditions, however, becomes liquid-permeable by applying an external force to the barrier, the use of such a device for isolating or purifying a biomolecule from a sample, a method for preparation of the device and a method for isolation or purification of any biomolecule using said device.

Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, L1, L2, L3, L4, L5, L6, M1, M2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

Abstract: Methods and reagents are disclosed for preparing a liquid solution of a receptor. The methods comprise combining in a liquid medium the receptor, a chelating agent and a C2-C6 polyol. An amount of the chelating agent and the C2-C6 polyol is sufficient to achieve a stable and active receptor in the liquid solution, which is maintained at a temperature of about 2° C. to about 40° C. The compositions may be employed in assays for the determination of analytes that include receptor-binding analytes.

Abstract: In a known method of measuring a target substance, comprising: providing a sample solution containing the target substance, a first reaction solution, and a second reaction solution; sequentially aspirating the sample solution and the first reaction solution, using a measuring apparatus equipped with a dispensing unit, into the dispensing unit; discharging them at a time from the dispensing unit, to bring them into contact with the second reaction solution, and to form a complex of the target substance and a first partner which is contained in at least one of the first reaction solution or the second reaction solution and reacts specifically with the target substance; and analyzing the resulting complex, an improved method capable of inhibiting a reaction which adversely affects measurement results is provided.

Abstract: Methods and reagents are disclosed for preparing a liquid solution of a receptor. The methods comprise combining in a liquid medium the receptor, a chelating agent and a C2-C6 polyol. An amount of the chelating agent and the C2-C6 polyol is sufficient to achieve a stable and active receptor in the liquid solution, which is maintained at a temperature of about 2° C. to about 40° C. The compositions may be employed in assays for the determination of analytes that include receptor-binding analytes.

Abstract: Fluorescent phenyl xanthene dyes are described that comprise any fluorescein, rhodamine or rhodol comprising a particular C9 phenyl ring. One or both of the ortho groups on the lower C9 phenyl ring is ortho substituted with a group selected from alkyl, heteroalkyl, alkoxy, halo, haloalkyl, amino, mercapto, alkylthio, cyano, isocyano, cyanato, mercaptocyanato, nitroso, nitro, azido, sulfeno, sulfinyl, and sulfino. In one embodiment, halo and/or hydroxy groups are used. Optimal dyes contain a lower C9 phenyl ring in which both ortho groups are the same and the lower ring exhibits some form a symmetry relative to an imaginary axis running from the phenyl rings point of attachment to the remainder of the xanthene dye through a point para to the point of attachment. The phenyl xanthene dyes may be activated. Furthermore, the phenyl xanthene dyes may be conjugated to one or more substances including other dyes.

Abstract: The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs.

Abstract: A subtractive corrective assay device and methodology, whereby ail required binding and label detection reagents are initially located within the detection zone. Application of a magnetic field is used to selectively remove bound label from the detection zone by means of paramagnetic particles. The relationship between measured label concentration before and after the application of a magnetic field within the detection zone is used to accurately measure analyte concentration within the sample.

Abstract: A specimen collection apparatus is provided. The specimen collection apparatus may include a container, a funnel for removable insertion in an opening of the container, a funnel cover; a removable seal, and a dispensing apparatus sealed within the funnel cover in a reagent-specific atmosphere. The dispensing apparatus may include a cap, a reagent housing attached to the cap, and a reagent designed to liquefy a specimen, stabilize the pH of the liquefied specimen, and be compatible with diagnostic procedures.

Abstract: The invention relates to a method for calibrating and/or adjusting an analytical device for chemical substances. A predetermined concentration of a chemical substance in a reference liquid is measured by mixing the reference liquid with a reagent for producing a color change, followed by irradiating with light of a predetermined wavelength. Based on the absorption of the light by the reference liquid, a concentration is determined, which is compared with the predetermined concentration of the reference liquid. In the case of which a calibrating and/or adjusting associated with the measurement process is possible without long interruptions of the measurement process, the predetermined concentration of the reference liquid is gained by mixing at least two standard, which contain different concentrations of the chemical substance.

Abstract: Methods are described for detection of autoimmune antibodies against the TSH receptor using TSH receptor chimeras, which preferably only contain the extracellular portion of the TSH wild type receptor modified as chimera, and are modified by highly immunogenic peptide residues or by enzymes suitable for detection, wherein the determination methods described allow simple detection of stimulating, blocking and neutral autoimmune antibodies.

Abstract: Provided are methods for determining the amount of reverse T3 in a sample using mass spectrometry. The methods generally involve ionizing reverse T3 in a sample and detecting and quantifying the amount of the ion to determine the amount of reverse T3 in the sample.

Abstract: The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody).

Abstract: The present invention pertains to the field of diagnostics for hyperthyroidism and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing hyperthyroidism. It also relates to a method for determining whether a compound is capable of inducing such hyperthyroidism in a subject and to a method of identifying a drug for treating hyperthyroidism. Furthermore, the present invention relates to a device and a kit for diagnosing hyperthyroidism.

Abstract: Method for obtaining an antibody or antibody fragment to a conformational epitope specific for oxidized, inactive human parathyroid hormone and fragments thereof; a method for removal of oxidized, inactive human parathyroid hormone from a sample of body fluid; methods of determining the concentration of active parathyroid hormone in a sample, and an in vitro method of diagnosis of renal failure or secondary hyperthyroidism in patients on dialysis.

Abstract: In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.

Abstract: Provided are methods for determining the amount of reverse T3 in a sample using mass spectrometry. The methods generally involve ionizing reverse T3 in a sample and detecting and quantifying the amount of the ion to determine the amount of reverse T3 in the sample.

Abstract: Methods and assays for oversulfated glycosaminoglycans are provided. In an embodiment, the present disclosure provides a method for detecting oversulfated glycosaminoglycan (OS-GAG) in a heparin sample. The method comprises placing the heparin sample onto a support comprising immobilized heparin and contacting the heparin sample on the support with a binding compound that attaches to the heparin and forms a heparin-binding compound complex. The binding compound also has a greater affinity for attaching to the OS-GAG than to the heparin in the heparin sample and forms an OS-GAG-binding compound complex. The method can further comprise detecting an amount of the heparin-binding compound complex on the support, and determining an amount of OS-GAG in the heparin sample based on the amount of the heparin-binding compound complex on the support.

Abstract: Devices and methods for performing a point of care diagnostic test for detecting and quantifying at least one analyte in a biological sample. The device may include an immunoassay apparatus and a holder with a variable angle stage for positioning the immunoassay apparatus relative to a light source and a detector device. In one embodiment, the device is based upon elastic light scattering, so the variation in the angle of incidence and angle of reflection are optimized to maximize signal generation due to elastic light scattering. The detector device may include a wired or wireless connection to a computer network for communicating with an electronic medical records system, uploading the amount or concentration of at least one analyte present in the sample to the electronic medical records system, or querying a decision support algorithm stored in a computer readable format. The detector device may further include an onboard interpretive algorithm.

Abstract: The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

Abstract: Provided are methods for determining the amount of reverse T3 in a sample using mass spectrometry. The methods generally involve ionizing reverse T3 in a sample and detecting and quantifying the amount of the ion to determine the amount of reverse T3 in the sample.

Abstract: An assay device includes: a liquid sample zone; a reagent zone downstream and in fluid communication with the sample zone. The reagent zone includes at least two reagent cells containing a reagent material and arranged in the reagent zone such that each reagent cell experiences substantially the same flow conditions of sample from the sample zone. The reagent cells divide the sample flow from the sample zone into multiple flow streams. Also includes are: one or more flow control elements disposed downstream from the reagent zone which combine the multiple flow streams into fewer flow streams; a detection zone in fluid communication with the reagent zone; and a wicking zone in fluid communication with the detection zone having a capacity to receive liquid sample flowing from the detection zone. The sample addition zone, the detection zone and the wicking zone define a fluid flow path.

Abstract: The invention provides an isolated antibody for the TSHR which is an antagonist of TSH. The invention also relates to methods of using antibodies of the invention.

Abstract: A fluid control and processing system for controlling fluid flow among a plurality of chambers comprises a body including a fluid processing region continuously coupled fluidicly with a fluid displacement region. The fluid displacement region is depressurizable to draw fluid into the fluid displacement region and pressurizable to expel fluid from the fluid displacement region. The body includes at least one external port. The fluid processing region is fluidicly coupled with the at least one external port. The fluid displacement region is fluidicly coupled with at least one external port of the body. The body is adjustable with respect to the plurality of chambers to place the at least one external port selectively in fluidic communication with the plurality of chambers.

Abstract: Provided are a base plate and a method for thyroxine immunoassay, which are capable of decreasing the signal change rate caused by temperature change in a high-sensitivity immunoassay method for thyroxine. A base plate for thyroxine immunoassay which has a conjugate of thyroxine or a derivative thereof and albumin immobilized thereon, and in which the ratio of the molecule number of thyroxine or a derivative thereof to the molecule number of albumin in the immobilized conjugate, is disclosed.

Abstract: Systems, methods, and test kits for monitoring and detecting variation in an analyte level in a fluid sample from an individual variation using a uniquely determined analyte threshold value. In one implementation, luteinizing hormone is the monitored analyte and is compared with the determined threshold value to predict the onset of ovulation for the individual.

Abstract: The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte

Abstract: An assay for identifying an individual having or at risk of developing vascular calcification, said assay comprising obtaining a blood sample from an individual and measuring the level of a vesicular compound in a matrix vesicle present in the blood sample from said individual; wherein an increased level of said compound indicates an individual at risk of developing vascular calcification.

Abstract: The present invention relates to immunoassay methods for measurements of concentrations of related analytes in samples of body fluids from different mammalian species. More particularly, it provides reagents and methods that may be used for assays of a mammalian antigen across a range of different mammalian species, using immunological reagents based on non-mammalian antibodies towards said mammalian antigen. Moreover, a calibrator or a set of calibrators is provided, assigned with concentration values for the said antigen for each of the different mammalian species. The advantage of this invention is that the analytical laboratories or veterinarians may use the same reagents and method to test a plurality of different mammalian species without having to use different immunoassay reagents for different mammalian species.

Abstract: Provided are methods of detecting the presence or amount of organified radioiodine, such as radioactive thyroxine, in a sample using mass spectrometry. For example, one aspect of the invention relates to a rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the simultaneous measurement of radioactive thyroxine and non-radioactive thyroxine in human serum/plasma.

Abstract: A non-radioisotopic method measures Free T3 and/or Free T4 in a sample of a non-human species, which can be a canine.

Abstract: A liquid reagent of a stabilized thyroid hormone-immobilized carrier, by which a thyroid hormone can be measured easily in a short time and at low cost, is provided. The liquid reagent of a thyroid hormone-immobilized carrier according to the present invention includes: a thyroid hormone-immobilized carrier; and a solvent, and a pH of the solvent containing the thyroid hormone-immobilized carrier is in a range from 8.7 to 11.5. The detection of a thyroid hormone using the liquid reagent of the present invention can be carried out by competitively binding a thyroid hormone in a sample and the thyroid hormone-immobilized carrier in the liquid reagent with an anti-thyroid hormone antibody and detecting a composite of the thyroid hormone-immobilized carrier and the anti-thyroid hormone antibody.

Abstract: Methods, systems and kits for the simultaneous or sequential analysis of one or more hormones by mass spectrometry are disclosed. The methods require minimal sample size and minimal preparation time. The methods comprise ionizing the hormones and analyzing the hormones by mass spectrometry. In addition, methods, systems and kits for the simultaneous or sequential analysis of free thyroxine (FT4) hormone and free-triiodothyronine (FT3) is disclosed comprising ionization of the FT4 and FT3 hormone in the negative mode using an electrospray source.

Abstract: A method including measuring time periods in which a reflex point of a subject is struck and a reflex response is observed. A method including determining a resting metabolic rate of a subject by applying the Kail-Waters equation. An apparatus including a striking instrument capable of delivering a kinetic energy to a reflex point of a subject; and a measurement instrument capable of being coupled to a subject and measuring a reflex response. A machine-readable storage medium containing executable program instructions which when executed cause a digital processing system to perform a method including determining time periods in which a reflex point is struck and a reflex response is observed. A machine-readable storage medium containing executable program instructions which when executed cause a digital processing system to perform a method including determining a resting metabolic rate of a subject by applying the Kail-Waters equation.

Abstract: This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of thyroid hormones and related antibodies in a serum sample, which can be used to evaluate thyroid functions and to diagnose thyroid diseases. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antibodies and antigens used for the detection of respective thyroid hormones and related antibodies in a serum sample.

Abstract: New devices and methods for diagnosis and compositions and methods for treatment of cancers use combinations of antimicrobial agents and agents that can reverse dormancy and hibernation pathways. We unexpectedly found that surprisingly low doses of anti-hibernation compounds can substantially inhibit cancer cell growth in vitro and can successfully treat cancers, including metastatic cancer. We also unexpectedly found that antimicrobial agents and anti-HDS compounds together can increase the degree of inhibition of cancer cell growth in a synergistic fashion. We conclude that combination therapy with antimicrobial agents and anti-HDS compounds can be effective in treating human patients with cancer.

Abstract: Thus this invention relates to a nanoparticle, useful for bioaffinity assays. The nanoparticle has a self-assembling shell built up of several protein and/or peptide subunits, which protein and/or peptide subunits can be of one or several different types, assembled in an organized manner to form the shell having an inner surface facing the inside and an outer surface facing the outside of said particle. One or several of the types of subunits have one or several first binding moieties per type of subunit with the binding moiety facing the outside of the particle for binding of any specific ligand binding protein; and the particle contains within its shell a marker and/or one or several of the types of subunits have one or several second binding moieties per type of subunit with the binding moiety facing the inside and/or the outside of the particle for binding a marker; and the marker or markers enables detection of the particle.

Abstract: A non-radioisotopic method of detecting thyroid analytes comprising detecting T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in a sample of a non-human species. Each one of these analytes in an assay profile includes non-radio isotopic measurement of T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in the sample from the non-human species. A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. Antibodies and autoantibodies are bound, and a precipitated or bound antigen-antigen or antibody-autoantibody complex is formed. The supernatant or surrounding fluid of the bound or precipitated antigen-antigen or antibody-autoantibody complex is then removed. The thyroid activity of the bound complex, precipitate, supernatant or surrounding fluid is measured. The thyroid analyte is at least one of T3, Free T3, T4 or Free T4.

Abstract: The present invention provides methods of detecting analytes using particles having different physico-chemical properties, such as buoyancy, size, density, spectral characteristics, and/or binding properties, in solution-based sandwich assays and solution-based competition assays. The methods can be performed using rotors and bench-top centrifuges and provide for rapid, qualitative and quantitative detection of analytes. The present invention also provides kits that can be used to perform the methods, and mixtures containing particles suitable for the methods.

Abstract: A non-radioisotopic method measures Free T3 and/or Free T4 in a sample of a non-human species, which can be a canine.

Abstract: The invention provides a method for testing a WT1-related disease, such as leukemia, a solid cancer, or an atypia, for diagnosing the disease, evaluating the course of cure and the prognosis of the disease more simply with high reliability, the method comprises measuring the amount of antibody against WT1 in a sample and using the measurement value and the time course of the value as a clinical marker for the testing.

Abstract: A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. Antibodies and autoantibodies are bound, and a precipitated or bound antigen-antibody or antigen-autoantibody complex is formed. The supernatant or surrounding fluid of the bound or precipitated antigen-antibody or antigen-autoantibody complex is then removed. The thyroid activity of the bound complex, precipitate, supernatant or surrounding fluid is measured. The thyroid analyte is at least one of T3, Free T3, T4 or Free T4.

Abstract: A non-radioisotopic method of detecting thyroid analytes comprising detecting T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in a sample of a non-human species. Each one of these analytes in an assay profile includes non-radio isotopic measurement of T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in the sample from the non-human species. A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. A non-radioisotopic method detects Free T4 in a sample of a non-human species.

Abstract: A non-radioisotopic method of detecting thyroid analytes comprising detecting T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in a sample of a non-human species. Each one of these analytes in an assay profile includes non-radio isotopic measurement of T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in the sample from the non-human species. A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. Antibodies and autoantibodies are bound, and a precipitated or bound antigen-antigen or antibody—autoantibody complex is formed. The supernatant or surrounding fluid of the bound or precipitated antigen-antigen or antibody-autoantibody complex is then removed. The thyroid activity of the bound complex, precipitate, supernatant or surrounding fluid is measured. The thyroid analyte is at least one of T3, Free T3, T4 or Free T4.

Abstract: A non-radioisotopic method of detecting thyroid analytes comprising detecting T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in a sample of a non-human species. Each one of these analytes in an assay profile includes non-radio isotopic measurement of T3, Free T3, T4, Free T4 and thyroglobulin autoantibody in the sample from the non-human species. A non-radioisotopic method detects T3AA and T4AA thyroid autoantibodies in a sample from a non-human species such as the canine species. A non-radioisotopic method detects Free T4 in a sample of a non-human species.

Abstract: A method including measuring time periods in which a reflex point of a subject is struck and a reflex response is observed. A method including determining a resting metabolic rate of a subject by applying the Kail-Waters equation. An apparatus including a striking instrument capable of delivering a kinetic energy to a reflex point of a subject; and a measurement instrument capable of being coupled to a subject and measuring a reflex response. A machine-readable storage medium containing executable program instructions which when executed cause a digital processing system to perform a method including determining time periods in which a reflex point is struck and a reflex response is observed. A machine-readable storage medium containing executable program instructions which when executed cause a digital processing system to perform a method including determining a resting metabolic rate of a subject by applying the Kail-Waters equation.

Abstract: A means for conveniently and accurately measuring thyroxine or thyronine present in the blood or the like is provided: a compound represented by general formula (I) below: wherein L represents a linear or branched-chain linker having 5 to 50 total atoms; X represents one or more thyroxines, thyronines, or residues of derivatives thereof, bound to the main chain and/or side chain of the linker represented by L, a conjugate in the form of the above compound bonded to an avidin protein, and an aqueous dispersion including a microparticles the surface of which is modified with the above conjugate.

Abstract: Methods, systems and kits for the simultaneous or sequential analysis of one or more hormones by mass spectrometry are disclosed. The methods require minimal sample size and minimal preparation time. The methods include ionizing the hormones and analyzing the hormones by mass spectrometry. In addition, methods, systems and kits for the simultaneous or sequential analysis of thyroid hormones are disclosed including ionization of the thyroid hormones in the negative mode using an electrospray source.